Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MDGL PT raised to $170 from $82 at Roth Capital
$MDGL PT raised to $170 from $82 at Roth
— Odi Bruckman (@odibro) December 11, 2017
2H 2018 - 1H 2019 will be a very painful 12 months for critics (haters) of Dan O’Oconnor IMO.
- potential 30%+ ORR in PISCES
- potential AA
- potential licensing deal / buyout
Can’t wait!
You are correct. (eom)
Comprehensive analysis of the clinical immuno-oncology landscape
https://academic.oup.com/annonc/advance-article/doi/10.1093/annonc/mdx755/4693829
I agree that Dan is at the right place at the right time. Looking forward to him doing some big pharma deals in 2018. He did 5 major ones for ADXS that got the share price as high as $30 but the drop in SP is what has ADXS shareholders upset with him. Maybe ADXS’ science/data deserves some blame too? I don’t know. Let’s see what he can accomplish with ONCS tech and data.
I disagree. Punit has brought the company only one dataset away from accelerated approval for anti-pd1 refractory population in melanoma. That’s a $500M market. He redirected company focus from monotherapy to combination therapy at the right time. He also invested in internal EP application technology at the right time, which will allow ONCS to replicate the combo success they are going to have in melanoma, in other visceral cancers. Do you have any response to address these points for our readers?
I think the company has said 1H’18. I’m guessing late Q1/early Q2.
These are important considerations Whalatane. Thank you for sharing. I will certainly take these into account.
SCMP Exploring Sale on Rumored Takeover Interest
https://www.biospace.com/article/unique-sucampo-exploring-sale-on-rumored-takeover-interest/
Most ONCS shareholders are going to withhold judgement on the new CEO until he gets at least a year. Let’s see how he does first.
Fair point. We will have to wait for p2 data in Q1/Q2 to be able to make this comparison. Until then it is all speculation.
Whalatane, Biotech Jim, and the board in general, would love to hear your thoughts on this tweet:
Now that the MC is over $100M, VKTX will fall in the coverage universe of reputed biotech analysts. The really big ones like GS, Citi may not cover until $500M MC but I think we could see some decent analysts pick up coverage in coming months. A good PT from them will help the stock.
Investors are certainly getting aware of MDGL. As they research the company, they will stumble upon VKTX. I think big pharmas will also take note. NASH is a really hot space and big pharmas are spending like there's no tomorrow to have a presence in the field. I wouldn't be surprised if Viking catches the eyes of some of them.
Thank you Whalatane and Biotech Jim for the informative discussion.
From an article comparing Viking’s NASH candidate vs Madrigal’s:
biotech jim from Biotech Values board:
Let’s do it!
Got back in today! (eom)
VKTX +18% on no news (eom).
SAGE (+50%/PM) triggers another burst of investor enthusiasm as oral depression drug scores in PhII
https://endpts.com/sage-triggers-another-burst-of-investor-enthusiasm-as-oral-depression-drug-scores-in-phii/
Market wanted to give them a higher valuation after MDGL data ($4.20+ premarket). Profit takers brought it down but management should have had some resolve and negotiated a higher offering price with the book runners pointing out this very valuation gap. So I agree with you.
Also they bungled KOL event. Should have done it after hip data and had Ligand rep discuss the data. Would have added some more weight IMO.
VKTX prices 5.90M* shares @ $2.50
https://finance.yahoo.com/news/viking-therapeutics-announces-pricing-12-010800610.html
*Assuming exercise of underwriter's option
Cancer R&D tips the scales at the FDA as active INDs climb to record high
https://endpts.com/cancer-rd-tips-the-scales-at-the-fda-as-active-inds-climb-to-record-high/
Scary!
More frightening video from Los Angeles as fires continue to spread this morning https://t.co/qJ1HzFIZKN Video taken by: @andrew1110
— Tornado Trackers (@tornadotrackers) December 6, 2017
Botox Suddenly Looks Less Invincible
https://www.bloomberg.com/gadfly/articles/2017-12-05/revance-data-botox-looks-less-invincible
Madrigal's stock soars on promising PhII data in NASH, but questions linger
https://endpts.com/madrigals-stock-soars-on-phase-ii-data-in-nash/
MDGL +42% premarket; Gave VKTX a lift despite its plunge on dilution news yesterday (the other NASH player with a THR agonist; its phase 2 data due Q1/early Q2)
As someone who is look in to bet on VK2809 and currently pursuing other stocks, this works well for me. Will look to load up around Feb’18. However I do hope for the board that MDGL data this month props this up. I wouldn’t mind buying at $3-4 come Feb. GLTA.
PS. Regarding this offering - did they terminate the LPC deal? If so, it’s a good sign IMO.
Piper ups Revance price target to $51 on 'impressive' data
https://thefly.com/landingPageNews.php?id=2650761
Analysts’ top 10 biotech takeover targets are concentrated in two key areas
https://endpts.com/analysts-top-10-biotech-takeover-targets-are-concentrated-in-two-key-areas/
He is at privately owned Trianni, Inc., another company that has a non-cash collaboration with Merck. He seems to have a thing for these companies.
Akari's Coversin to treat paroxysmal nocturnal hemoglobinuria (PNH) is a potential competitor to Alexion's blockbuster drug Soliris. COBALT trial open label single arm phase II data on 6 patients (rare disease) due this weekend at #ash2017. Akari has the green light from the FDA to go ahead with a phase 3 trial in Q1 2018.
AKTX—
$aktx https://t.co/mOBufFw0Ad Bullish -Exec chairman buys 600k
— R (@Lucy3370) October 27, 2017
Shares of recent 4mil share 2dary- $3 mil investment. Strong insider buy
No PR from the company so I don’t believe so.
AKTX—Akari Therapeutics to Host Investor and Analyst Event During the 59th American Society of Hematology Meeting
https://globenewswire.com/news-release/2017/12/04/1220266/0/en/Akari-Therapeutics-to-Host-Investor-and-Analyst-Event-During-the-59th-American-Society-of-Hematology-Meeting.html
Company to webcast event December 10, 2017, at 8:00 p.m. ET
Anyone follow this company and have any thoughts on the data that is going to be shared? Took a small position today. Any insights would be appreciated. Thanks!
FYI a list of companies that are having analysts events/receptions at #ASH17. Hope they are webcast, but unfortunately not all always are:
— Brad Loncar (@bradloncar) December 3, 2017
Sat: $AMGN $INCY $BGNE
Sun: $AKTX $CELG $BLUE $TGTX
Mon: $GBT $SGEN $KPTI $JUNO
Yes. Always good to check the overall market indices, the IBB, and how other biotechs/pharmas are trading. You don’t need a company specific news to drive the price either way. The sector often drags down or lifts individual stocks.
Akari Therapeutics to Host Investor and Analyst Event During the 59th American Society of Hematology Meeting
Company to webcast event December 10, 2017, at 8:00 p.m. ET
https://globenewswire.com/news-release/2017/12/04/1220266/0/en/Akari-Therapeutics-to-Host-Investor-and-Analyst-Event-During-the-59th-American-Society-of-Hematology-Meeting.html
Akili's video game therapy hits goal in pivotal ADHD trial
http://www.fiercebiotech.com/medtech/akili-s-videogame-therapy-hits-goal-pivotal-adhd-trial
I had a question regarding repatriation w.r.t. foreign subsidiaries of US multinationals. Let's forget about the tax reform bill for a moment and picture the status quo. In case of big pharmas, Merck for example, is there a tax reason why it chooses to collaborate with US biotechs through one of its foreign subsidiaries like Merck Sharp & Dohme BV or MSD International GmbH? Are partnership payments (upfront or future) by a foreign subsidiary of a US company not subject to repatriation tax?